A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Status:	Completed
Conditions:	Blood Cancer, Hematology, Hematology
Therapuetic Areas:	Hematology, Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	11/3/2017
Start Date:	December 9, 2014
End Date:	October 10, 2017

A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

To assess the safety and tolerability, characterize the dose limiting toxicities (DLTs) and
identify the maximally tolerated dose (MTD) of Elotuzumab administered in combination with
either Lirilumab or Urelumab in subjects with multiple myeloma.

Allocation:

- Part1: Non-randomized

- Part2: Randomized

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Subjects must have histological confirmation of multiple myeloma with measurable
disease (per International Myeloma Working Group (IMWG) criteria):

- Relapsed/refractory multiple myeloma, subjects who are post autologous transplant
and have achieved very good partial response (VGPR) or complete response (nCR)
with minimal residual disease (MRD)

We found this trial at

sites

Local Institution

Pamplona, Navarra 31008

from

Pamplona,